OncBioMune Announces Term Sheet with EOC Pharma for Development of Telatinib
March 14, 2017 09:45 ET
|
OncBioMune Pharmaceuticals, Inc.
BATON ROUGE, LA--(Marketwired - March 14, 2017) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) ("OncBioMune" or the "Company"), a clinical stage biopharmaceutical company engaged in the development...
OncBioMune Acquires Vitel Laboratorios, Gains Two Revenue Generating Drugs, Robust Pipeline and Extensive Distribution Network
March 13, 2017 08:00 ET
|
OncBioMune Pharmaceuticals, Inc.
BATON ROUGE, LA--(Marketwired - March 13, 2017) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) ("OncBioMune" or the "Company"), a clinical stage biopharmaceutical company engaged in the development...
OncBioMune Announces Cancer Vaccine Poster Presentation at the 2017 American Association for Cancer Research Meeting
February 02, 2017 09:59 ET
|
OncBioMune Pharmaceuticals, Inc.
BATON ROUGE, LA--(Marketwired - February 02, 2017) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) ("OncBioMune" or the "Company"), a clinical stage biopharmaceutical company engaged in the...
Latest Clinical Data from OncBioMune Supports Safety and Therapeutic Profile of ProscaVax for Prostate Cancer for Upcoming Phase 2 Clinical Trials
January 26, 2017 15:47 ET
|
OncBioMune Pharmaceuticals, Inc.
BATON ROUGE, LA--(Marketwired - January 26, 2017) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) ("OncBioMune" or the "Company"), a clinical stage biopharmaceutical company engaged in the...
Departments of Urology and Oncology Approve Protocol for OncBioMune's Phase 2/3 Trial of ProscaVax for Prostate Cancer in Mexico
January 18, 2017 14:50 ET
|
OncBioMune Pharmaceuticals, Inc.
BATON ROUGE, LA--(Marketwired - January 18, 2017) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) ("OncBioMune" or the "Company"), a clinical stage biopharmaceutical company engaged in the...
OncBioMune Submitting Clinical Trial of World's First Early-Stage Prostate Cancer Vaccine to The Cancer Therapy Evaluation Program (CTEP) at the National Cancer Institute
January 10, 2017 08:00 ET
|
OncBioMune Pharmaceuticals, Inc.
BATON ROUGE, LA--(Marketwired - January 10, 2017) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) ("OncBioMune" or the "Company"), a clinical stage biopharmaceutical company engaged in the...
Patients Pre-Screened for OncBioMune Pharmaceuticals Phase 2/3 Trial of ProscaVax for Prostate Cancer
December 28, 2016 09:36 ET
|
OncBioMune Pharmaceuticals, Inc.
BATON ROUGE, LA--(Marketwired - December 28, 2016) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) ("OncBioMune" or the "Company"), a clinical stage biopharmaceutical company engaged in the...
OncBioMune Awarded Patent in Europe Protecting Novel Cancer Vaccine Technology
December 12, 2016 09:28 ET
|
OncBioMune Pharmaceuticals, Inc.
BATON ROUGE, LA--(Marketwired - December 12, 2016) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) ("OncBioMune" or the "Company"), a clinical stage biopharmaceutical company engaged in the...
OncBioMune and the Clinical Trial Investigators Have Agreed Upon the Protocol for Their Phase 2 Trial of Novel Vaccine for Early Stage Prostate Cancer
December 08, 2016 09:00 ET
|
OncBioMune Pharmaceuticals, Inc.
BATON ROUGE, LA--(Marketwired - December 08, 2016) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) ("OncBioMune"), a clinical stage biopharmaceutical company engaged in the development of novel...
OncBioMune Provides Update on Acquisition of Vitel Laboratorios
December 07, 2016 08:30 ET
|
OncBioMune Pharmaceuticals, Inc.
BATON ROUGE, LA--(Marketwired - December 07, 2016) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) ("OncBioMune"), a clinical stage biopharmaceutical company engaged in the development of novel...